HUYA, Quintiles to co-develop HBI-8000
HBI-8000 has now entered into a Phase I clinical trial in the US under an IND application with the FDA. HBI-8000 trial is designed to assess safety, tolerability
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.